Asthma inhalers are critical for delivering small amounts of medication to people's lungs to improve breathing and help prevent asthma attacks, but those tiny puffs add up to a large environmental ...
Switching from a metered-dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...
Dr. Miguel Divo, a lung specialist at Brigham and Women’s Hospital, sits in an exam room, across from one of his patients with asthma. Joel Rubinstein, a retired psychiatrist, is about to get a ...
Please provide your email address to receive an email when new articles are posted on . “Many health care systems are discussing a transition to dry-powder inhalers that have a lower carbon footprint ...
Concerns over health care’s carbon footprint typically revolve around issues like overly-air-conditioned hospitals and single-use medical supply waste. But researchers like Stanford University’s ...
Reducing the use of metered-dose inhalers for asthma could shrink the carbon footprint while achieving cost savings if less expensive brands of dry powder inhalers are used, according to new research ...
New reports reveal the most commonly prescribed inhaler in the U.S. may actually be contributing to climate change. While these inhalers are critically important to saving lives and making it easier ...
Asthma sufferers could sharply reduce their carbon footprint by swapping commonly used inhalers for “greener” alternatives, a study from the University of Cambridge has found. By swapping metered-dose ...
When you think of prescription inhalers, you might think of a medical device used to treat respiratory illnesses such as asthma. Although inhalers help treat breathing conditions, they can also affect ...
Struggling with your asthma medicine? An asthma inhaler works most effectively if you deliver your medication slowly, so this is where a spacer device can be useful to help you achieve this goal. Many ...
> Pearl Therapeutics reports positive Phase IIb results from a study of glycopyrrolate, a long-acting muscarinic agonist delivered twice daily through a metered dose inhaler, for patients with ...
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, ...